Pfizer and Sangamo Therapeutics will soon resume a Phase 3 trial of their gene therapy for the blood disorder hemophilia A, nearly a year after safety concerns forced its suspension.
Specifically, the companies said Thursday evening they plan to resume recruiting patients for the study this month and restart dosing with the treatment in October.
The study was originally paused last fall due to safety concerns over blood clotting. The gene therapy, dubbed giroctocogene fitelparvovec, is meant to treat people with severe hemophilia A, who either lack or have low levels of a needed blood clotting protein.
